Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | GNAO1 | P09471 | 7/20 | 0.43 |
| ▸ | GNAI3 | P08754 | 6/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | GBA2 | Q9HCG7 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7508966 | 0.96 | GNAO1 (0.47) | LTA4HGNAO1GNAI3GNAI1MEN1 | |
| SCHEMBL7511056 | 0.95 | GNAO1 (0.44) | LTA4HGNAO1GNAI3GNAI1MEN1 | |
| SCHEMBL7510250 | 0.89 | HRH3 (0.44) | LTA4HGNAO1GNAI3GNAI1 | |
| SCHEMBL9042102 | 0.87 | GNAI3 (0.37) | GNAO1GNAI3GNAI1 | |
| SCHEMBL6553947 | 0.87 | GNAI3 (0.53) | LTA4HGNAO1GNAI3GNAI1MEN1 | |
| SCHEMBL7510266 | 0.85 | KDM4E (0.34) | LTA4HHTTMAPT | |
| Bromide SCHEMBL28255534 | 0.85 | GNAI3 (0.52) | LTA4HGNAO1GNAI3GNAI1MEN1 | |
| SCHEMBL9433020 | 0.85 | GNAO1 (0.55) | GNAO1GNAI3GNAI1 | |
| SCHEMBL10773791 | 0.85 | GNAO1 (0.55) | GNAO1GNAI3GNAI1 | |
| SCHEMBL10593959 | 0.85 | GNAO1 (0.55) | GNAO1GNAI3GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008069726-A1 | TREATMENT OF RESISTANT SCHIZOPHRENIA AND OTHER CNS DISORDERS BY THE USE OF THIOXANTHENES | COPHARM (LU) | 2008-06-12 | — | — | WO | claimed |
| US-20080139573-A1 | Treatment of resistant Schizophrenia and other CNS disorders | COPHARM (LU) | 2008-06-12 | — | — | US | claimed |
| WO-2008069726-A1 | TREATMENT OF RESISTANT SCHIZOPHRENIA AND OTHER CNS DISORDERS BY THE USE OF THIOXANTHENES | COPHARM (LU) | 2008-06-12 | — | — | WO | disclosed |
| US-20080139573-A1 | Treatment of resistant Schizophrenia and other CNS disorders | COPHARM (LU) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139573-A1 | Treatment of resistant Schizophrenia and other CNS disorders | CHRNA10, SLC6A3, ZFX | LTA4H 1838/4885GNAO1 591/4885GNAI3 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.